Epidemiology of Dementia

Slides:



Advertisements
Similar presentations
APO E Genetic Screening for Alzheimers and Metabolic Individuality.
Advertisements

The Memory Assessment and Treatment Service (MATS)
Third in the Annual R13 AGS Conference Series, “From Bedside to Bench”
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Curtin University is a trademark of Curtin University of.
FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Grandparenting and health in Europe: a longitudinal analysis Di Gessa G, Glaser K and Tinker A Institute of Gerontology, Department of Social Science,
EPIDEMIOLOGY AND GENETICS OF ALZHEIMER´S DISEASE
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Epidemiology of Peripheral Vascular Disease Sohail Ahmed School of Population and Health Sciences.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Introduction: East / west gradients for deaths attributed to stroke tend to be greater than those for coronary heart disease and high rates in the east.
Chapter 11 Diet and Health
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
Mild Cognitive Impairment
Epidemiology of Dementia in Canada: Information from the Canadian Study of Health and Aging.
MILD COGNITIVE IMPAIRMENT IN PATIENTS WITH CAROTID DISEASE Irena Martinic Popovic 1, M.D, Arijana Lovrencic-Huzjan 1, M.D, Ph. D, Ana-Maria Simundic 2,
GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen.
Disability free Life Expectancy Carol Jagger University of Leicester EHEMU Team European Population Day: Ageing IUSSP Tours 2005.
Recognition of Dementia Syed Zaman Consultant Physician Geriatric Medicine Palmerston North Hospital.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
Better Your Brain It's never too late to make smart lifestyle changes that will protect your health in years to come. Boost brainpower and keep your mind.
Health Status of Australian Adults. The health status of Australians is recognised as good and is continually improving. The life expectancy for males.
Chronic disease and its impact on disability and the need for LTC Carol Jagger Experts' Seminar on Ageing and Long-Term Care Needs 20 May 2011.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
The Healthy Body, Healthy Brain Campaign Alaska Commission on Aging Alaska Division of Public Health Alaska Mental Health Trust Legislative Health Caucus.
Dementia Dr Deborah Stinson Sutton CMHT for Older People
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
METABOLIC SYNDROME, INCIDENCE OF DIABETES AND MORTALITY AMONG ELDERLY: THE ITALIAN LONGITUDINAL STUDY ON AGING M Noale, S Maggi, F Limongi, P Siviero,
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Wayne Rosamond, et al. Circulation 2007;115; e69-e171.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
CAROLINE HARADA, M.D. ASSOCIATE PROFESSOR OF MEDICINE UAB DIVISION OF GERONTOLOGY, GERIATRICS, AND PALLIATIVE CARE NOVEMBER 2013 Dementia.
Very low CHD mortality among men aged in several states in the United States Akira Sekikawa, MD, PhD, PhD Lewis H Kuller, MD, DrPH Department of.
Epidemiology of Alzheimer’s Disease
Ethnicity and Cardiovascular Disease Africans Americans.
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.
Additional Assessments. Clinicians are encouraged to communicate with the interprofessional team about other resources and next steps in terms of additional.
The Aging Process from a Quality of Life Perspective Ingalill Rahm Hallberg, Professor, Director of the Swedish Institute for Health Sciences Assistant.
Used to be called Dementia Neurocognitive Disorders.
Alzheimer’s Disease Stephanie Aparicio May 4, 2011 Period 5.
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.
Improvements needed in the care of people living with Dementia.
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
The Malfunctioning Mind: Degenerative Diseases of the Brain
Dementia : A growing global issue
Alzheimer’s disease: Interventions and New Findings
Chapter 11 Diet and Health
DEMENTIA Shenae Whitfield & Kate Maddock.
Epidemiology: Assignment 3
Changing demographics and the impact on dementia
The Relationship Between Mental and Physical Health
Dementia Risk Prediction Development of the first tool for LMICs (WS2)
Ageing with ideal cardiovascular risk factors
PSY 6670 Diagnosis & Treatment Planning Lecture 2: Neurocognitive Disorders Treatment Planning Joel Fairbanks, Ph.D.
From the Indianapolis – Ibadan Dementia Research Project.
Summer School on Neuroscience & Aging
Steps to a Healthy Brain
The Memory Assessment and Treatment Service (MATS)
Risk Factors and Therapies for Vascular Dementia:
Presentation transcript:

Epidemiology of Dementia Stefania Maggi CNR-Institute of Neuroscience Aging Branch Padova, Italy

Worldwide population 65+ milion The proportion of Older people will Increase from 7% to 12% Source: United Nation, Population Aging and Development, 2009

Worldwide dementia: the numbers will double every twenty years!! Million Ferri et al., 2005, Lancet 366:2112-17

Epidemiology studying dementia Give the real size of dementia: Prevalence Incidence Risk factors Protective factors (biologic, behavioural, socio-economic) Dementia diagnosis!

Diagnosis: Revised criteria NINDS-ADRDA (McKhann, 2011) for all-cause dementia Cognitive or behavioural (neuropsychiatric) symptoms Interfere with work or usual activities Represent a decline from previous functioning levels Are not explained by delirium Cognitive impairment established by objective cognitive assessment, self- and proxy-reported, and finally confirmed by neuropsychological testing Deficits in at least two following domains: Acquire and remember new information Reasoning and handling complex task Poor judgment Visuospatial abilities Language Changes in personality, behaviour, or comportment

Prevalence studies

Worldwide Prevalence of dementia Qiu et al., 2009, Dialogues. Clin. Neurosci. 11:111-128

EURODEM STUDY Mean prevalence of dementia: 6,4 % 65+ years old Kuopio Study (Finland) Kungsholmen Project (Sweden) Odense Study (Denmark) Rotterdam Study (Netherlands) Melton Mowbray (UK) MCR-ALPHA (UK) PAQUID (France) Pamplona Study (Spain) Zaragoza Study (Spain) ZARADEMP (Spain) ILSA (Italy) Mean prevalence of dementia: 6,4 % 65+ years old

EURODEM STUDY Kuopio Study (Finland) Kungsholmen Project (Sweden) Odense Study (Denmark) Rotterdam Study (Netherlands) Melton Mowbray (UK) MCR-ALPHA (UK) PAQUID (France) Pamplona Study (Spain) Zaragoza Study (Spain) ZARADEMP (Spain) ILSA (Italy)

General Conclusions on Dementia prevalence studies AD prevalence increases with age doubling every 5 years from age 65 Prevalence of AD is higher than prevalence of VaD Need to better define the “mixed” form of dementia Trends in prevalence reflects the influence of the incidence of disease and survival Prevalence and incidence studies based on either hospital records or volunteers underestimate the AD Poor sensitivity of screening test

Incidence studies

Worldwide dementia Incidence Qiu et al., 2009, Dialogues. Clin. Neurosci. 11:111-128

Per 1000 persons-year EURODEM

General Conclusions on Dementia Incidence studies Incidence increases by 2 times about every 5 years Female population has an increased risk of AD Incidence is influenced by applied diagnostic criteria Differences among countries are more pronounced for AD and VaD comparison respect to other forms of dementia

Risk and Protective factors for dementia

Risk Factors Protective Factors APOE-4 allele: susceptibility gene Vascular RF (obesity, high cholesterol) Vascular disease (diabetes, hypertension, TIA, WM lesion) Lifestyle (heavy alcohol intake, smoking) High serum Homocysteine Inflammation Toxic exposure (aluminium, mercury) Traumatic brain injury Depression Antioxidant (Vitam E and C) High serum levels of folate and Vitamin B12 Polyunsaturated fatty acid (Omega 3) High education level Social network and engagement Regular physical activity Active mind

Survival of patients with dementia

ILSA S tudy ILSA coorte: dementia vs.non D ILSA coorte P<0.05

Survival in ILSA coorte: disability According to the Global Burden of Disease estimates, dementia Contributes 11.2% of years lived with disability in people 60+, more than stroke (9.5%), musculoskeletal ds (8.9%), CVD (5%), cancer (2.4%) Demented Non demented P<0.05 P<0.05

Hazard Ratio and 95% CI of death in the ILSA cohort Noale M et al. Dement geriatr Cogn Disord 2003

I COSTI DELLA MALATTIA DI ALZHEIMER COSTO MEDIO ANNUO : circa 43,000.00 Euro (Gambina, et al, 2010) Due studi italiani precedenti (Co.Dem., Bianchetti 1998; Cavallo e Fattore 1997) calcolavano un valore medio tra i 93 e i 98 milioni. In tutti questi studi i costi indiretti, sostenuti in massima parte dalle famiglie, incidono per circa 80% sul totale. I costi associati alla gestione della Demenza di Alzheimer incidono sul PIL, di nazioni diverse, dal 0,6% al 4% circa. Gli studi italiani (Cavallo, Fattore 1997 e Trabucchi 1994) stimavano in Italia una percentuale pari a 1,16% sul PIL, che oggi sono stimati intorno al 4,5%.

Epidemiologia della Demenze: conclusioni

Dementia is a devastating neurodegenerative disorder that will grow up overtime. Multidisciplinary approches to assess dementia (genetic, epidemiologist, clinicians) Prevalence and Incidence increase exponentially with age (65 +) worldwide Take into account Risk and Protective factors In patients with dementia, a comprehensive approach including any comorbidities may improve the prognosis quoad vitam e quoad valetudinem